Table 1.

Baseline characteristics of patients in long-term follow-up who remained in remission through end of study

Patients remaining in remission (n = 13)*Other patients (n = 13)All patients (n = 26)
Median age (range), y 52.0 (21-81) 58.0 (25-82) 55.5 (21-82) 
Female, n (%) 10 (77) 5 (38) 15 (58) 
ECOG performance status, n (%)    
 Grade 0 6 (46) 5 (38) 11 (42) 
 Grade 1 5 (38) 5 (38) 10 (38) 
 Grade 2 2 (15) 3 (23) 5 (19) 
Disease diagnosis    
 Systemic ALCL 9 (69) 10 (77) 19 (73) 
 ALK+ 3 (23) 3 (12) 
 ALK 6 (46) 10 (77) 16 (62) 
 Non-ALCL 4 (31) 3 (23) 7 (27) 
 AITL 1 (8) 1 (8) 2 (8) 
 ATLL 1 (8) 1 (8) 2 (8) 
 PTCL-NOS 2 (15) 2 (8) 
 EATL 1 (8) 1 (4) 
Median time from diagnosis to first dose (range), d 29.0 (9-71) 39.0 (7-109) 31.5 (7-109) 
Stage at diagnosis, n (%)    
 I 3 (23) 3 (12) 
 II 2 (15) 2 (15) 4 (15) 
 II 3 (23) 3 (23) 6 (23) 
 IV 5 (38) 8 (62) 13 (50) 
IPI score    
 0-1 5 (38) 3 (23) 8 (31) 
 2-3 7 (54) 7 (54) 14 (54) 
 4-5 1 (8) 3 (23) 4 (15) 
Median SPD in cm2 (range) 20.6 (4-68) 17.7 (2-173) 20.0 (2-173) 
Patients remaining in remission (n = 13)*Other patients (n = 13)All patients (n = 26)
Median age (range), y 52.0 (21-81) 58.0 (25-82) 55.5 (21-82) 
Female, n (%) 10 (77) 5 (38) 15 (58) 
ECOG performance status, n (%)    
 Grade 0 6 (46) 5 (38) 11 (42) 
 Grade 1 5 (38) 5 (38) 10 (38) 
 Grade 2 2 (15) 3 (23) 5 (19) 
Disease diagnosis    
 Systemic ALCL 9 (69) 10 (77) 19 (73) 
 ALK+ 3 (23) 3 (12) 
 ALK 6 (46) 10 (77) 16 (62) 
 Non-ALCL 4 (31) 3 (23) 7 (27) 
 AITL 1 (8) 1 (8) 2 (8) 
 ATLL 1 (8) 1 (8) 2 (8) 
 PTCL-NOS 2 (15) 2 (8) 
 EATL 1 (8) 1 (4) 
Median time from diagnosis to first dose (range), d 29.0 (9-71) 39.0 (7-109) 31.5 (7-109) 
Stage at diagnosis, n (%)    
 I 3 (23) 3 (12) 
 II 2 (15) 2 (15) 4 (15) 
 II 3 (23) 3 (23) 6 (23) 
 IV 5 (38) 8 (62) 13 (50) 
IPI score    
 0-1 5 (38) 3 (23) 8 (31) 
 2-3 7 (54) 7 (54) 14 (54) 
 4-5 1 (8) 3 (23) 4 (15) 
Median SPD in cm2 (range) 20.6 (4-68) 17.7 (2-173) 20.0 (2-173) 

AITL, angioimmunoblastic T-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; EATL, enteropathy-associated T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified; SPD, sum of the products of the diameters.

*

Patients with objective response who entered long-term follow-up and remained in remission through end of study with no consolidative stem cell transplant or new anticancer therapy.

Patients with objective response who either experienced PD (n = 7) or discontinued the study because of death (n = 5) or withdrawal of consent (n = 1).